CANF Can-Fite BioPharma Ltd. stock chart & analysis
Conviction 45Scan · Wed, Nov 18, 2026Can-Fite BioPharma Ltd. (CANF) closed at $1.48 (-3.27%) on Nov 18, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 34, RS Rating 5, -88.0% from its 52-week high, -63.0% year to date.
Why CANF moved
From the StockSetups movers recaps that covered CANF, newest first. A recap states what was known that day.
- Premarket+57.3%
Multiple sources this morning — including Yahoo Finance, TipRanks, GuruFocus, and Stock Titan — report that Can-Fite's Phase 2a pancreatic cancer study with Namodenoson has achieved its primary safety endpoint and demonstrated durable survival outcomes in advanced disease.
Premarket Stock Movers — July 1, 2026: Why DXF, LHAI, LGCL, CELZ & CANF Are Surging →
CANF technical analysis
Trend
CANF is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 22.5% below the 50-day ($1.91) and 51.3% below the 200-day ($3.04). ADX(14) at 69 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 34, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.
Volume and volatility
Volume on the latest session ran 0.3× its 20-day average. It trades about $125,189 a day on average. ATR(14) is $0.0991, 6.7% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The chart pattern's support is $1.46 and its resistance $2.10. The 52-week range is $1.42 to $12.30; price is 88.0% below the high and 4.2% above the low. The VWAP anchored at the 52-week high is $4.89, above price.
Performance
CANF returned -4.5% (1 week), -21.7% (1 month), -55.8% (3 months), -57.2% (6 months), -79.6% (1 year), -63.0% (year to date).
About Can-Fite BioPharma Ltd.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Listed 2012 · 5 employees
Insider activity
SEC Form 4 transactions in CANF
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Farbstein Motti CEO, CFO and COO · Options to Purchase Ordinary Shares · 2026-06-04 | Grant | 24K | $0 | 2026-06-04 | 2026-06-08 |
Fishman Pnina Chief Scientific Officer · Options to Purchase Ordinary Shares · 2026-06-04 | Grant | 24K | $0 | 2026-06-04 | 2026-06-08 |
SEC filings
EDGAR filings in CANF · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.